In the phase 3 VERITAC-2 trial, vepdegestrant improved PFS compared to fulvestrant in patients with previously treated HR+/HER2-negative advanced breast cancer containing ESR1 mutation [23]. This evidence concerns the gene ERBB2 and breast carcinoma.